These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 934359)
1. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Waldmeier PC; Delini-Stula A; Maître L Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):9-14. PubMed ID: 934359 [TBL] [Abstract][Full Text] [Related]
2. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. Kato T; Dong B; Ishii K; Kinemuchi H J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508 [TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927 [TBL] [Abstract][Full Text] [Related]
4. Proceedings: Lack of significance of MAO-B for in vivo deamination of dopamine. Waldmeier PC; Maître L Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R2. PubMed ID: 1143400 [No Abstract] [Full Text] [Related]
5. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. Brannan T; Prikhojan A; Martínez-Tica J; Yahr MD J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):79-89. PubMed ID: 9620056 [TBL] [Abstract][Full Text] [Related]
6. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Kumagae Y; Matsui Y; Iwata N Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113 [TBL] [Abstract][Full Text] [Related]
7. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf I; Youdim MB; Finberg JP J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937 [TBL] [Abstract][Full Text] [Related]
8. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. Wachtel SR; Abercrombie ED J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420 [TBL] [Abstract][Full Text] [Related]
9. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain. Fagervall I; Ross SB J Neurochem; 1986 Aug; 47(2):569-76. PubMed ID: 3734795 [TBL] [Abstract][Full Text] [Related]
10. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism. Azzaro AJ; King J; Kotzuk J; Schoepp DD; Frost J; Schochet S J Neurochem; 1985 Sep; 45(3):949-56. PubMed ID: 3928811 [TBL] [Abstract][Full Text] [Related]
12. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. Schoepp DD; Azzaro AJ J Neurochem; 1981 Jun; 36(6):2025-31. PubMed ID: 6787175 [TBL] [Abstract][Full Text] [Related]
13. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. Finberg JP; Wang J; Goldstein DS; Kopin IJ; Bankiewicz KS J Neurochem; 1995 Sep; 65(3):1213-20. PubMed ID: 7643100 [TBL] [Abstract][Full Text] [Related]
14. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism. Waldmeier PC; Maître L Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):133-40. PubMed ID: 1012333 [TBL] [Abstract][Full Text] [Related]
15. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat. Garrett MC; Soares-da-Silva P Neuropharmacology; 1990 Oct; 29(10):875-9. PubMed ID: 2123970 [TBL] [Abstract][Full Text] [Related]
16. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694 [TBL] [Abstract][Full Text] [Related]
17. Reversibility of the interaction of CGP 11305 A with MAO A in vivo. Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309 [TBL] [Abstract][Full Text] [Related]
18. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. O'Carroll AM; Fowler CJ; Phillips JP; Tobbia I; Tipton KF Naunyn Schmiedebergs Arch Pharmacol; 1983 Apr; 322(3):198-202. PubMed ID: 6408492 [TBL] [Abstract][Full Text] [Related]
19. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Green AR; Youdim MB Br J Pharmacol; 1975 Nov; 55(3):415-22. PubMed ID: 1203627 [TBL] [Abstract][Full Text] [Related]
20. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]